XiAn International Medical Investment Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 1.29, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.25, suggesting limited short-term liquidity to cover immediate liabilities. The company's market price of 4.49 CNY and a market cap of 10.05 billion CNY reflect a price-to-book ratio of 3.03, indicating that the market values the company at a premium to its book value. Profitability metrics show a return on equity of -9.44% and a return on assets of -3.22%, both significantly below the industry median, indicating poor performance in generating returns for shareholders and asset utilization. The company reported a net loss of 313.08 million CNY, with an operating loss of 400.73 million CNY, highlighting challenges in maintaining profitability. The company's revenue is primarily concentrated in its core operations, with no disclosed segment breakdown. However, the geographic exposure is not specified in the available data, making it difficult to assess regional concentration risks. The company's operating cash flow of 1.28 billion CNY provides some cushion, but the free cash flow of -145.67 million CNY indicates that the company is not generating sufficient cash to fund operations and capital expenditures. The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. The capital expenditure of -262.47 million CNY suggests ongoing investment in infrastructure, but the negative free cash flow indicates that these investments are not yet generating positive returns. The company's risk assessment highlights a key flag of negative net cash after subtracting total debt, signaling potential liquidity constraints. Recent events and filings do not provide specific details on strategic initiatives or operational changes. The company's financial performance and risk profile suggest a need for careful monitoring of its liquidity and profitability trends. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding.